Nifural 0.2, 5 ml 90 ml bottle suspension for oral administration

Active ingredients Nifuroxazide

Country of originRussia

ManufacturerFarmVilar NPO LLC

Release form Suspension for oral administration, 200 mg / 5 ml - 90 ml of suspension in a vial.

1 bottle together with a measuring spoon and instructions for use are placed in a cardboard box.

Keep out of reach of children

Dosage form

A yellow suspension with a banana scent.

Structure

5 ml of suspension contains:

active substance: nifuroxazide 200 mg

auxiliary substances: sucrose (sugar), sodium hydroxide, methyl parahydroxybenzoate, carbomer, citric acid monohydrate, banana flavor, ethanol (ethyl alcohol) 96%, purified water.

Special conditions

When treating diarrhea concomitantly with nifuroxazide therapy, rehydration therapy is necessary.

Children under 3 years of age should be treated under medical supervision.

In the case of bacterial diarrhea with signs of systemic damage (deterioration of the general condition, fever, symptoms of intoxication or infection), you should consult a doctor to decide on the appointment of systemic antimicrobials.

If symptoms of hypersensitivity (shortness of breath, skin rash, itching) appear, you should stop taking the drug.

Drinking alcohol during nifuroxazide therapy is prohibited.

Due to the content of methyl parahydroxybenzoate, the drug may cause allergic reactions (possibly delayed).

Nifural® suspension contains 1000 mg of sucrose in 5 ml.

Accordingly, the content of sucrose in a single dose of 2.5 ml of the suspension is 0.04165 bread units" (XE), and in a single dose of 5 ml - 0.0833 XE.

The daily dose of sucrose is 0.0833 XE when taking 2.5 ml of suspension 2 times a day

and 0.125 XE when taking 2.5 ml of the suspension 3 times a day.

The daily dose of sucrose is 0.250 XE when taking 5 ml of the suspension 3 times a day and 0.333 XE when taking 5 ml of the suspension 4 times a day.

The content of 96% ethanol in Nifural® suspension is 1%.

The minimum single dose of the drug, corresponding to 100 mg of nifuroxazide (2.5 ml of suspension), contains 0.02 g of ethanol (in terms of absolute alcohol), and the maximum daily dose, corresponding to 800 mg of nifuroxazide (5 ml of suspension 4 times a day), contains 0.16 g of ethanol (calculated as absolute alcohol).

Influence on the ability to drive vehicles and mechanisms

The drug has no effect on the ability to drive vehicles and mechanisms.

Drug interactions

Simultaneous use with drugs that cause the development of disulfiram-like reactions, drugs that inhibit the function of the central nervous system is not recommended.

If you are taking other medications

(including over-the-counter) consult your doctor before using Nifural®.

Pharmacodynamics

Nifuroxazide is an antimicrobial agent derived from nitrofuran.

Blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell.

Destroys the membrane of a microbial cell, reduces the production of toxins by microorganisms.

Highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp, Shigella spp., Clostridium perfingens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp.

Weakly sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae and Proteus indologenes.

Resistant to nifuroxazide: Klebsiella spp, Proteus mirabilis, Providencia spp, Pseudomonas spp.

Does not disturb the balance of intestinal microflora.

In case of acute bacterial diarrhea, it restores intestinal eubiosis.

When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Pharmokinetics

After oral administration, nifuroxazide is practically not absorbed from

digestive tract and exerts its antibacterial effect exclusively in the intestinal lumen.

Nifuroxazide is excreted by the intestines: 20% is unchanged, and the rest of the amount of nifuroxazide is chemically altered.

Indications

Acute bacterial diarrhea, proceeding without deterioration of the general condition, fever, intoxication.

Contraindications

Hypersensitivity to nifuroxazide, nitrofuran derivatives and other components of the drug, pregnancy, neonatal period up to 1 month, prematurity, fructose intolerance, glucose-galactose malabsorption syndrome, sucrase and isomaltase deficiency.

Carefully

Liver disease, alcoholism, traumatic brain injury, brain disease, lactation period, childhood.

Application during pregnancy and during breastfeeding

In animal studies, no teratogenic effect was found.

However, it is not recommended to take nifuroxazide during pregnancy as a precautionary measure.

During the breastfeeding period, breastfeeding may continue.

feeding in the case of a short course of drug treatment.

It is necessary

consult a doctor.

Overdose

Overdose symptoms are not known.

Treatment is symptomatic.

Side effects

Allergic reactions (skin rash, urticaria, Quincke's edema, anaphylactic shock).

If any of the side effects indicated in the instructions are aggravated, or you

have noticed any other side effects not listed in the instructions, inform your doctor.

Dosage

200mg / 5ml x 90ml

Indications

Acute bacterial diarrhea, proceeding without deterioration of the general condition, fever, intoxication.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

INN / Active ingredient

Nifuroxazide

Contraindications

Hypersensitivity to nifuroxazide, nitrofuran derivatives and other components of the drug, pregnancy, neonatal period up to 1 month, prematurity, fructose intolerance, glucose-galactose malabsorption syndrome, sucrase and isomaltase deficiency.

With care - liver disease, alcoholism, traumatic brain injury, brain disease, lactation, childhood.

Specifications

Category

Diarrhea

Scope of the drug

Gastrointestinal tract

Release form

Oral suspension

Manufacturer country

Russia

Package quantity, pcs

one

Vacation conditions

Without recipe

Brand name

PharmVILAR

Components

measuring spoon

The amount of the dosage form in the primary package

90 ml

Primary packaging type

Bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Antimicrobial agent - nitrofuran

Anatomical and therapeutic characteristics

A07AX03 Nifuroxazide

Dosage form

Suspension for oral administration

Expiration date in days

1095

Dosage (volume) of the substance in the preparation

nifuroxazide 200 mg

Package weight, g

205

Information on technical characteristics, delivery set, country of manufacture "